Zonisamide

Phase 3

Eisai (ESALY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Epilepsy; Paediatric Partial Onset Seizures

View Full Landscape

Drug Information

Target Indication

Epilepsy; Paediatric Partial Onset Seizures

Clinical Trial

NCT00566254

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/31/2016

Zonisamide Viatris (previously Zonisamide Mylan)

Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ESALY

Eisai

Healthcare•North America•NASDAQ

Related Pipeline

Eperisone hydrochloride and Diclofenac sodiumPhase 3

Acute Musculoskeletal Spasm Due to Low Back Pain

T-614Phase 3

Rheumatoid Arthritis